types of glp 1 receptor agonists Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research GLP-1 receptor agonists for individualized

There are significant safety concerns, including reports of adverse events such as nausea, vomiting, diarrhea, and more severe hospitalizations, often due to incorrect measurement or administration errors

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases

We first reported that the internalization of GLP-1 is compromised in the presence of GIPR full agonist IUB68 (22)

A drug based on that molecule, called Exenatide, became the first approved GLP-1 receptor agonist for treating diabetes in 2005

The market for GLP-1 RAs is dominated by Novo Nordisk, Eli Lilly, AstraZeneca, Bristol Myers Squibb and GSK